

## **CLINICAL APPLICATION OF PIMONIDAZOLE HCl**

### **1996-2012**

1. Raleigh, J. A., Dewhurst, M. W., and Thrall, D. E. Measuring tumor hypoxia. *Semin Radiat Oncol*, 6: 37-45, 1996.
2. Kennedy, A. S., Raleigh, J. A., Perez, G. M., Calkins, D. P., Thrall, D. E., Novotny, D. B., and Varia, M. A. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. *Int J Radiat Oncol Biol Phys*, 37: 897-905, 1997.
3. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Jr., Novotny, D. B., and Varia, M. A. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. *Cancer Res*, 58: 3765-3768, 1998.
4. Varia, M. A., Calkins-Adams, D. P., Rinker, L. H., Kennedy, A. S., Novotny, D. B., Fowler, W. C., Jr., and Raleigh, J. A. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. *Gynecol Oncol*, 71: 270-277, 1998.
5. Haustermans, K., Hofland, I., Van de Pavert, L., Geboes, K., Varia, M., Raleigh, J., and Begg, A. C. Diffusion limited hypoxia estimated by vascular image analysis: comparison with pimonidazole staining in human tumors. *Radiother Oncol*, 55: 325-333, 2000.
6. Olive, P. L., Durand, R. E., Raleigh, J. A., Luo, C., and Aquino-Parsons, C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. *Br J Cancer*, 83: 1525-1531, 2000.
7. Raleigh, J. A., Chou, S. C., Calkins-Adams, D. P., Ballenger, C. A., Novotny, D. B., and Varia, M. A. A clinical study of hypoxia and metallothionein protein expression in squamous cell carcinomas. *Clin Cancer Res*, 6: 855-862, 2000.
8. Wijffels, K. I., Kaanders, J. H., Rijken, P. F., Bussink, J., van den Hoogen, F. J., Marres, H. A., de Wilde, P. C., Raleigh, J. A., and van der Kogel, A. J. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. *Br J Cancer*, 83: 674-683, 2000.
9. Begg, A. C., Janssen, H., Sprong, D., Hofland, I., Blommesteijn, G., Raleigh, J. A., Varia, M., Balm, A., Van Velthuyzen, L., Delaere, P., Sciote, R., and Haustermans, K. M. G. Hypoxia and perfusion measurements in human tumors--initial experience with pimonidazole and IUdR. *Acta Oncol*, 40: 924-928, 2001.
10. Nordmark, M., Loncaster, J., Chou, S. C., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J., and Raleigh, J. A. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma. *Int J Radiat Oncol Biol Phys*, 49: 581-586, 2001.
11. Olive, P. L., Aquino-Parsons, C., MacPhail, S. H., Liao, S. Y., Raleigh, J. A., Lerman, M. I., and Stanbridge, E. J. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. *Cancer Res*, 61: 8924-8929, 2001.

12. Olive, P. L., Banath, J. P., and Aquino-Parsons, C. Measuring hypoxia in solid tumours- is there a gold standard? *Acta Oncol*, *40*: 917-923, 2001.
13. Raleigh, J. A., Chou, S. C., Bono, E. L., Thrall, D. E., and Varia, M. A. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. *Int J Radiat Oncol Biol Phys*, *49*: 569-574, 2001.
14. Raleigh, J. A., Thrall, D. E., and Varia, M. A. Development and clinical application of pimonidazole as a marker for tumor hypoxia. *Recent Res. Devel. Cancer*, *3*: 189-201, 2001.
15. Arcasoy, M. O., Amin, K., Karayal, A. F., Chou, S. C., Raleigh, J. A., Varia, M. A., and Haroon, Z. A. Functional significance of erythropoietin receptor expression in breast cancer. *Lab Invest*, *82*: 911-918, 2002.
16. Janssen, H. L., Haustermans, K. M., Sprong, D., Blommestijn, G., Hofland, I., Hoebbers, F. J., Blijweert, E., Raleigh, J. A., Semenza, G. L., Varia, M. A., Balm, A. J., van Velthuysen, M. L., Delaere, P., Scot, R., and Begg, A. C. HIF-1alpha, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. *Int J Radiat Oncol Biol Phys*, *54*: 1537-1549, 2002.
17. Kaanders, J. H., Wijffels, K. I., Marres, H. A., Ljungkvist, A. S., Pop, L. A., van den Hoogen, F. J., de Wilde, P. C., Bussink, J., Raleigh, J. A., and van der Kogel, A. J. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. *Cancer Res.*, *62*: 7066-7074, 2002.
18. Airley, R. E., Loncaster, J., Raleigh, J. A., Harris, A. L., Davidson, S. E., Hunter, R. D., West, C. M., and Stratford, I. J. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding. *Int. J. Cancer*, *104*: 85-91, 2003.
19. Azuma, Y., Chou, S. C., Lininger, R. A., Murphy, B. J., Varia, M. A., and Raleigh, J. A. Hypoxia and differentiation in squamous cell carcinomas of the uterine cervix: pimonidazole and involucrin. *Clin Cancer Res*, *9*: 4944-4452, 2003.
20. Begg, A. C. Is HIF-1alpha a good marker for tumor hypoxia? *Int. J. Radiat. Oncol. Biol. Phys.*, *56*: 917-919, 2003.
21. Bussink, J., Kaanders, J. H., and van der Kogel, A. J. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. *Radiother Oncol*, *67*: 3-15, 2003.
22. Hoskin, P. J., Sibtain, A., Daley, F. M., and Wilson, G. D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. *Br J Cancer*, *89*: 1290-1297, 2003.
23. Nordmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S. C., Ladekarl, M., Havsteen, H., Lindegaard, J. C., Davidson, S. E., Varia, M., West, C., Hunter, R., Overgaard, J., and Raleigh, J. A. Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. *Radiother Oncol*, *67*: 35-44, 2003.
24. Vordermark, D. and Brown, J. M. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? *Strahlenther. Onkol.*, *179*: 801-811, 2003.
25. Chou, S. C., Azuma, Y., Varia, M. A., and Raleigh, J. A. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. *Br. J. Cancer*, *90*: 728-735, 2004.

26. Hoskin, P. J., Sibtain, A., Daley, F. M., Saunders, M. I., and Wilson, G. D. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. *Radiother Oncol*, 72: 159-168, 2004.
27. Janssen, H. L., Hoebbers, F. J., Sprong, D., Goethals, L., Williams, K. J., Stratford, I. J., Haustermans, K. M., Balm, A. J., and Begg, A. C. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. *Radiother. Oncol.*, 70: 91-97, 2004.
28. Airley, R. E., Phillips, R. M., Evans, A. E., Double, J., Burger, A. M., Feibig, H. H., West, C. M., and Stratford, I. J. Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: Results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. *Int J Oncol*, 26: 1477-1484, 2005.
29. Arcasoy, M. O., Amin, K., Chou, S. C., Haroon, Z. A., Varia, M., and Raleigh, J. A. Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. *Clin Cancer Res*, 11: 20-27, 2005.
30. Hoogsteen, I. J., Peeters, W. J., Marres, H. A., Rijken, P. F., van den Hoogen, F. J., van der Kogel, A. J., and Kaanders, J. H. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. *Radiother Oncol*, 76: 213-218, 2005.
31. Janssen, H. L., Haustermans, K. M., Balm, A. J., and Begg, A. C. Hypoxia in head and neck cancer: how much, how important? *Head Neck*, 27: 622-638, 2005.
32. Murdoch, C. and Lewis, C. E. Macrophage migration and gene expression in response to tumor hypoxia. *Int J Cancer*, 117: 701-708, 2005.
33. Williams, K. J., Parker, C. A., and Stratford, I. J. Exogenous and endogenous markers of tumour oxygenation status: definitive markers of tumour hypoxia? *Adv Exp Med Biol*, 566: 285-294, 2005.
34. Carnell, D. M., Smith, R. E., Daley, F. M., Saunders, M. I., Bentzen, S. M., and Hoskin, P. J. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. *Int J Radiat Oncol Biol Phys*, 65: 91-99, 2006.
35. Durand, R. E. and Aquino-Parsons, C. The fate of hypoxic (pimonidazole-labelled) cells in human cervix tumours undergoing chemo-radiotherapy. *Radiother Oncol*, 80: 138-142, 2006.
36. Jankovic, B., Aquino-Parsons, C., Raleigh, J. A., Stanbridge, E. J., Durand, R. E., Banath, J. P., MacPhail, S. H., and Olive, P. L. Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. *Cytometry B Clin Cytom*, 70: 45-55, 2006.
37. Jonathan, R. A., Wijffels, K. I., Peeters, W., de Wilde, P. C., Marres, H. A., Merckx, M. A., Oosterwijk, E., van der Kogel, A. J., and Kaanders, J. H. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. *Radiother Oncol*, 79: 288-297, 2006.
38. Nordmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S. C., Gebiski, V., West, C., Lindegaard, J. C., Havsteen, H., Davidson, S. E., Hunter, R., Raleigh, J. A., and Overgaard, J. The prognostic value of pimonidazole and tumour pO<sub>2</sub> in human cervix carcinomas after radiation therapy: A prospective international multi-center study. *Radiother Oncol*, 80: 123-131, 2006.

39. Raleigh, J. A., Arcasoy, M. O., Amikn, K., Lininger, R. A., and Varia, M. A. Comparison between exogenous and endogenous hypoxia markers in human cancer: pimonidazole and erythropoietin. . *In: American Association for Cancer Research 97th Annual Meeting, Washington, DC, 2006, Abstract #3631.*
40. van Laarhoven, H. W., Kaanders, J. H., Lok, J., Peeters, W. J., Rijken, P. F., Wiering, B., Ruers, T. J., Punt, C. J., Heerschap, A., and van der Kogel, A. J. Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. *Int J Radiat Oncol Biol Phys*, *64*: 473-482, 2006.
41. Hoogsteen, I. J., Marres, H. A., Bussink, J., van der Kogel, A. J., and Kaanders, J. H. Tumor microenvironment in head and neck squamous cell carcinomas: Predictive value and clinical relevance of hypoxic markers. A review. *Head Neck*, 2007; *29*(6): 591-604.
42. Hoskin, P. J., Carnell, D. M., Taylor, N. J., Smith, R. E., Stirling, J. J., Daley, F. M., Saunders, M. I., Bentzen, S. M., Collins, D. J., d'Arcy, J. A., and Padhani, A. P. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. *Int J Radiat Oncol Biol Phys*, *68*: 1065-1071, 2007.
43. Le, Q. T. Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches. *Int J Radiat Oncol Biol Phys*, *69*: S56-58, 2007.
44. Westbury, C. B., Pearson, A., Nerurkar, A., Reis-Filho, J. S., Steele, D., Peckitt, C., Sharp, G., and Yarnold, J. R. Hypoxia can be detected in irradiated normal human tissue: a study using the hypoxic marker pimonidazole hydrochloride. *Br J Radiol*, *80*: 934-938, 2007.
45. Hoogsteen IJ, Marres HA, van der Kogel AJ, Kaanders JH. The hypoxic tumour microenvironment, patient selection and hypoxia-modifying treatments. *Clin Oncol (R Coll Radiol)* 2007; *19*: 385-96.
46. Silva P, Homer JJ, Slevin NJ, et al. Clinical and biological factors affecting response to radiotherapy in patients with head and neck cancer: a review. *Clin Otolaryngol* 2007; *32*: 337-45.
47. Bussink, J., van der Kogel, A. J., and Kaanders, J. H. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome: in regard to Evans et al. (*Int J Radiat Oncol Biol Phys* 2007;*69*:1024-1031). *Int J Radiat Oncol Biol Phys*, *70*: 1616, 2008.
48. Greijer, A. E., Delis-van Diemen, P. M., Fijneman, R. J., Giles, R. H., Voest, E. E., van Hinsbergh, V. W., and Meijer, G. A. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. *Virchows Arch*, *452*: 535-544, 2008.
49. Sluimer, J. C., Gasc, J. M., van Wanroij, J. L., Kisters, N., Groeneweg, M., Sollewijn Gelpke, M. D., Cleutjens, J. P., van den Akker, L. H., Corvol, P., Wouters, B. G., Daemen, M. J., and Bijnens, A. P. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. *J Am Coll Cardiol*, *51*: 1258-1265, 2008.
50. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. *Lancet Oncol* 2008; *9*: 288-96.

51. Bache M, Kappler M, Said HM, Staab A, Vordermark D. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. *Curr Med Chem* 2008; 15: 322-38.
52. Wijffels KI, Marres HA, Peters JP, Rijken PF, van der Kogel AJ, Kaanders JH. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas. *Oral Oncol* 2008; 44: 335-44.
53. Wijffels, K. I., Hoogsteen, I. J., Lok, J., Rijken, P. F., Marres, H. A., de Wilde, P. C., van der Kogel, A. J., and Kaanders, J. H. No detectable hypoxia in malignant salivary gland tumors: preliminary results. *Int J Radiat Oncol Biol Phys*, 73: 1319-1325, 2009.
54. Hoogsteen IJ, Lok J, Marres HA, et al. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. *Eur J Cancer* 2009; 45: 2906-14.
55. Newbold K, Castellano I, Charles-Edwards E, et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. *Int J Radiat Oncol Biol Phys* 2009; 74: 29-37.
56. Varia, M. A., Lee, D. Y-W. and Raleigh, J.A. Oral Pimonidazole HCl as tumor hypoxia marker. Report of first clinical use –pharmacokinetics and tolerance. *Int J Radiat Oncol Biol Phys*, 75 (3)Suppl: S539-S540, 2009.
57. Herrick AL, Gorodkin R, Jeziorska M, Stratford IJ. Testing for hypoxia in forearm skin of patients with systemic sclerosis, assessed by pimonidazole. *J Rheumatol* 2010; 37: 1968-9.
58. Foti R, Zucchelli S, Biagioli M, et al. Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. *J Biol Chem* 2010; 285: 18565-74.
59. Olive PL, Banuelos CA, Durand RE, Kim JY, Aquino-Parsons C. Endogenous and radiation-induced expression of gammaH2AX in biopsies from patients treated for carcinoma of the uterine cervix. *Radiother Oncol* 2010; 94: 82-9.
60. Varia, M.A., Lee, D.Y. and Raleigh, J.A. Comparison Between Glut-1 expression and hypoxia in squamous cell carcinoma of the uterine cervix using oral pimonidazole as hypoxia marker. *Int J Radiat Oncol Biol Phys*, 81(2)Suppl.: S705-S705, 2011.
61. Donaldson SB, Betts G, Bonington SC, et al. Perfusion Estimated with Rapid Dynamic Contrast-Enhanced Magnetic Resonance Imaging Correlates Inversely with Vascular Endothelial Growth Factor Expression and Pimonidazole Staining in Head-and-Neck Cancer: A Pilot Study. *Int J Radiat Oncol Biol Phys* 2011; 81: 1176-83.
62. Kristiansen G, Hu J, Wichmann D, et al. Endogenous myoglobin in breast cancer is hypoxia-inducible by alternative transcription and functions to impair mitochondrial activity: a role in tumor suppression? *J Biol Chem* 2011; 286: 43417-28.
63. Nijkamp MM, Hoogsteen IJ, Span PN, et al. Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. *Radiother Oncol* 2011; 101(1): 165-70.
64. Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. *BMC Cancer* 2011; 11: 167.

65. Wennemers M, Bussink J, Scheijen B, et al. Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. *Breast Cancer Res* 2011; 13: R82 (DOI: 10.1186/bcr2934).
66. Betts GN, Eustace A, Patiar S, et al. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. *Eur J Cancer* 2012.
67. Hoogsteen IJ, Marres HA, van den Hoogen FJ, et al. Expression of EGFR Under Tumor Hypoxia: Identification of a Subpopulation of Tumor Cells Responsible for Aggressiveness and Treatment Resistance. *Int J Radiat Oncol Biol Phys* 2012; 84(3): 807-14. (DOI: 10.1016/j.ijrobp.2012.01.002).
68. Janssens GO, Rademakers SE, Terhaard CH, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. *J Clin Oncol* 2012; 30: 1777-83.
69. Mandeville HC, Ng QS, Daley FM, et al. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. *Radiology* 2012; 264: 581-9.
70. Verstraete M, Debucquoy A, Devos E, et al. Investigation of possible endogenous hypoxia markers in colorectal cancer. *Int J Radiat Biol* 2012.